contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


klaria-pharma-holding-ab-klaria-year-end-report-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapeutic areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of an alginate-based polymer film. The film is attached to the patient's oral mucosa, which enables the distribution of drugs in the body. The headquarters are located in Uppsala.

Klaria Pharma Holding

Klaria Year-End Report Q4 20251 January-31 December 2025SummaryFourth quarter of 2025 The group in total - Net sales 0.0 MSEK (0.0 MSEK) - Other income 0.0 MSEK (0.0 MSEK) - R&D expenses for...

<div class="abstract">Klaria Year-End Report Q4 20251 January-31 December 2025</div>SummaryFourth quarter of 2025 The group in total - Net sales 0.0 MSEK (0.0 MSEK) - Other income 0.0 MSEK (0.0 MSEK) - R&amp;D expenses for the quarter amounted to 4.8 MSEK (9.3 MSEK) - Profit after tax amounted to -8.4 MSEK (-15.6 MSEK) - Earnings per share for the quarter amounted to -0.03 SEK (-0.11 SEK) - Cash flow from operating activities amounted to -2.4 MSEK (1.3 MSEK) - Liquid assets on the balance sheet date amounted to 0.3 MSEK (0.6 MSEK) - Group equity as of December 31 amounted to -3.9 MSEK (3.3 MSEK) - Equity in the parent company as of December 31 amounted to 88.8 MSEK 80.6 MSEK) The period January-December 2025 The group in total - Net sales 9.0 MSEK (2.2 MSEK) - Other income 0.0 MSEK (0.1 MSEK) - R&amp;D expenses for the period amounted to 20.1 MSEK (22.1 MSEK) - Profit after tax amounted to -38.9 MSEK (-47.7 MSEK) - Earnings per share for the period amounted to -0.21 SEK (-0.38 SEK) - Cash flow from operating activities amounted to -35.0 MSEK (-11.9 MSEK) - The company received 9.7 MSEK from the issue of convertibles in June - The company received 31.6 MSEK after issue costs from the issue of 101,217,381 shares in July<div>This disclosure contains information that Klaria Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 20-02-2026 16:00 CET.</div>